Table 3. Serum PSA and hs-CRP levels and TRUS findings at admission and follow-up.
| Variable | All recruited patients
at admission, N=64 |
Patients with follow-up completed, N=50 | |||
|---|---|---|---|---|---|
| Admission | 1 month | 3 month | P value | ||
| Serum PSA, ng/mL, median (IQR) | 2.15(1.18-3.02) | 1.95(1.15-2.55) | 1.1(0.5-1.8) | 0.43(0.3-1) | <0.001 |
| Serum hs-CRP, mg/dL, median(IQR) | 2.23 (1.85-2.75) | 2.26( 1.81-2.75) | -- | 0.41(0.16- 1.52) | <0.001 |
| TRUS findings | |||||
| Prostate volume in mL, median (IQR) | 25.4(18.9-34) | 24.1(18.72-34.39) | -- | 21.6(17.7-29.3) | <0.001 |
| Normal, n(%) | 38 (59) | 26(52) | -- | 37(74) | NA |
| Benign prostatic enlargement, n(%) | 5(8) | 3(6) | 3(6) | ||
| Focal hypoechogenicity, n(%) | 6(9) | 6(12) | -- | 5(1) | NA |
| Nodules, n(%) | 2(3) | 1(2) | -- | -- | NA |
| Abscess, n(%) | 1(2) | 1(2) | -- | -- | NA |
| Calcifications, n(%) | 13(20) | 13(26) | -- | 13(26) | NA |
| Seminal vesicle involvement, n(%) | 1(2) | 1(2) | -- | -- | NA |
PSA, prostate-specific antigen; hs-CRP, high sensitivity C-reactive protein; TRUS, transrectal ultrasound; IQR, interquartile range.